Paper Details

  1. Home
  2. Paper Details

Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART.

Author: AgbajiOche, DarinKristin M, EjelioguEmeka, ImadeGodwin, KankiPhyllis J, McIlleronHelen M, OdaiboGeorgina, OgucheStephen, OgunbosiBabatunde O, OkonkwoProsper, OladokunRegina, OlaleyeDavid, RawizzaHolly E, ScarsiKimberly K, WiesnerLubbe

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study evaluated the safety and pharmacokinetics of rifabutin in 15 children with TB/HIV coinfection who were receiving lopinavir/ritonavir. Ribafutin (2.5 mg/kg daily) achieved plasma concentrations comparable to adults, and favorable HIV and TB treatment outcomes were observed. Severe neutropenia was uncommon and resolved without treatment interruption. These findings support the use of rifabutin for TB/HIV coinfected children requiring lopinavir/ritonavir.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment options are limited for TB/HIV-coinfected children who require PI-based ART. Rifabutin is the preferred rifamycin for adults on PIs, but the one study evaluating rifabutin with PIs among children was stopped early due to severe neutropenia. METHODS: We evaluated rifabutin safe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879135/

データ提供：米国国立医学図書館（NLM）

Rifabutin for TB/HIV-Coinfected Children

The treatment of tuberculosis (TB) and HIV co-infection in children presents unique challenges. This research investigates the use of rifabutin, a rifamycin antibiotic, in conjunction with lopinavir/ritonavir-based antiretroviral therapy (ART) for children with TB/HIV co-infection. The study sought to evaluate rifabutin's safety and pharmacokinetic profile in this vulnerable population. The researchers enrolled 15 co-infected children between the ages of 3 and 15 years and monitored their response to rifabutin treatment. They discovered that rifabutin achieved plasma concentrations comparable to those seen in adults, and the treatment was associated with favorable HIV and TB outcomes.

Safety and Efficacy of Rifabutin

While rifabutin-associated neutropenia, a reduction in white blood cell count, was observed in some patients, it was generally mild and resolved without treatment interruption or serious consequences. The researchers concluded that rifabutin appears to be a safe and effective treatment option for TB/HIV-coinfected children requiring lopinavir/ritonavir-based ART.

A Light in the Desert

These findings provide a beacon of hope for treating TB/HIV co-infection in children, a challenging condition that often requires specialized care. The researchers' dedication to finding safe and effective treatment options for this population is truly commendable. The data suggest that rifabutin could be a valuable tool in the arsenal of clinicians treating TB/HIV co-infected children.

Dr.Camel's Conclusion

This research is a testament to the power of science to find solutions for complex health challenges. The researchers' dedication to improving the lives of children with TB/HIV co-infection shines brightly, offering hope for a healthier future. This research reminds us that even in the vast desert of medical unknowns, there are oases of progress waiting to be discovered.

Date :
  1. Date Completed 2021-07-05
  2. Date Revised 2023-11-11
Further Info :

Pubmed ID

33294914

DOI: Digital Object Identifier

PMC7879135

Related Literature

Article Analysis
・Effects of rifamycin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.